These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

64 related items for PubMed ID: 10779810

  • 1. [LGD1069: an antagonist to the X retinoid receptor].
    Lansiaux A, Formstecher P, Bailly C.
    Bull Cancer; 2000 Mar; 87(3):235-8. PubMed ID: 10779810
    [No Abstract] [Full Text] [Related]

  • 2. Bexarotene ligand pharmaceuticals.
    Hurst RE.
    Curr Opin Investig Drugs; 2000 Dec; 1(4):514-23. PubMed ID: 11249708
    [Abstract] [Full Text] [Related]

  • 3. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
    Song JI, Lango MN, Hwang JD, Drenning SD, Zeng Q, Lamph WW, Grandis JR.
    Cancer Res; 2001 Aug 01; 61(15):5919-25. PubMed ID: 11479234
    [Abstract] [Full Text] [Related]

  • 4. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
    Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH.
    Cancer Epidemiol Biomarkers Prev; 2002 May 01; 11(5):467-74. PubMed ID: 12010861
    [Abstract] [Full Text] [Related]

  • 5. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
    Agarwal VR, Bischoff ED, Hermann T, Lamph WW.
    Cancer Res; 2000 Nov 01; 60(21):6033-8. PubMed ID: 11085524
    [Abstract] [Full Text] [Related]

  • 6. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
    Fu J, Ding Y, Huang D, Li H, Chen X.
    Cancer Lett; 2007 Apr 08; 248(1):153-63. PubMed ID: 17027148
    [Abstract] [Full Text] [Related]

  • 7. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
    Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH.
    Cancer Res; 2002 Nov 15; 62(22):6376-80. PubMed ID: 12438218
    [Abstract] [Full Text] [Related]

  • 8. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
    Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW.
    Cancer Res; 1998 Feb 01; 58(3):479-84. PubMed ID: 9458093
    [Abstract] [Full Text] [Related]

  • 9. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
    Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA.
    Cancer Res; 1996 Dec 15; 56(24):5566-70. PubMed ID: 8971154
    [Abstract] [Full Text] [Related]

  • 10. Identification of the first retinoid X, receptor homodimer antagonist.
    Canan Koch SS, Dardashti LJ, Hebert JJ, White SK, Croston GE, Flatten KS, Heyman RA, Nadzan AM.
    J Med Chem; 1996 Aug 16; 39(17):3229-34. PubMed ID: 8765503
    [No Abstract] [Full Text] [Related]

  • 11. A new rexinoid for cutaneous t-cell lymphoma.
    Cheng SX, Kupper T.
    Arch Dermatol; 2001 May 16; 137(5):649-52. PubMed ID: 11346343
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
    Gamage SD, Bischoff ED, Burroughs KD, Lamph WW, Gottardis MM, Walker CL, Fuchs-Young R.
    J Pharmacol Exp Ther; 2000 Nov 16; 295(2):677-81. PubMed ID: 11046105
    [Abstract] [Full Text] [Related]

  • 13. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.
    Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH.
    Cancer Res; 2006 Dec 15; 66(24):12009-18. PubMed ID: 17178900
    [Abstract] [Full Text] [Related]

  • 14. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A, Lamph WW, Bissonnette RP.
    Lung Cancer; 2005 Oct 15; 50(1):9-18. PubMed ID: 15993980
    [Abstract] [Full Text] [Related]

  • 15. Determinants of retinoid X receptor transcriptional antagonism.
    Cavasotto CN, Liu G, James SY, Hobbs PD, Peterson VJ, Bhattacharya AA, Kolluri SK, Zhang XK, Leid M, Abagyan R, Liddington RC, Dawson MI.
    J Med Chem; 2004 Aug 26; 47(18):4360-72. PubMed ID: 15317450
    [Abstract] [Full Text] [Related]

  • 16. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
    Yen WC, Lamph WW.
    Prostate; 2006 Feb 15; 66(3):305-16. PubMed ID: 16245282
    [Abstract] [Full Text] [Related]

  • 17. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR, Dragnev KH.
    Oncologist; 2005 Jan 15; 10(1):22-33. PubMed ID: 15632250
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.